BriaCell Therapeutics Corp.
BCTXW · NASDAQ
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $107 | $83 | $20 | $19 |
| Gross Profit | -$107 | -$83 | -$20 | -$19 |
| % Margin | – | – | – | – |
| R&D Expenses | $21,271 | $26,752 | $15,337 | $8,021 |
| G&A Expenses | $5,934 | $0 | $7,936 | $7,267 |
| SG&A Expenses | $5,934 | $5,973 | $7,936 | $7,267 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$15,292 |
| Operating Expenses | $27,205 | $32,726 | $23,272 | -$3 |
| Operating Income | -$27,386 | -$32,808 | -$23,272 | -$15,289 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $653 | $27,954 | $2,970 | -$11,689 |
| Pre-Tax Income | -$26,733 | -$4,854 | -$26,770 | -$34,368 |
| Tax Expense | $0 | $0 | -$153 | $31 |
| Net Income | -$26,487 | -$4,716 | -$20,302 | -$11,581 |
| % Margin | – | – | – | – |
| EPS | -62.6 | -42.99 | -1.74 | -1.73 |
| % Growth | -45.6% | -2,370.7% | -0.6% | – |
| EPS Diluted | -62.6 | -42.99 | -1.74 | -1.73 |
| Weighted Avg Shares Out | 423 | 110 | 15,620 | 15,494 |
| Weighted Avg Shares Out Dil | 423 | 110 | 15,620 | 15,518 |
| Supplemental Information | – | – | – | – |
| Interest Income | $121 | $284 | $891 | $137 |
| Interest Expense | $37 | $0 | $0 | $1 |
| Depreciation & Amortization | $107 | $83 | $15 | $19 |
| EBITDA | -$26,589 | -$4,772 | -$27,221 | -$34,047 |
| % Margin | – | – | – | – |